WuXi XDC Cayman, Inc. (HK:2268)
:2268
Want to see HK:2268 full AI Analyst Report?
Top Page
WuXi XDC Cayman, Inc.
(2268)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$50.00
▼(-8.76% Downside)
Action:Downgraded
Date:04/29/26
The score is driven primarily by strong financial performance—high margins, solid growth, and a conservative balance sheet—partly offset by uneven cash-flow conversion. Technicals are weak-to-neutral with the stock below key moving averages and slightly negative MACD. Valuation is a meaningful headwind given the high P/E and no dividend yield provided.
Positive Factors
Specialized ADC CDMO franchise
A focused ADC CDMO model creates durable competitive advantages: technical know-how across ADC discovery, analytical, and GMP manufacturing raises switching costs, fosters long-term partnerships, and aligns with structural outsourcing by biopharma for complex modalities.
Negative Factors
Volatile free cash flow / weak cash conversion
Inconsistent conversion of earnings into free cash reduces financial flexibility for sustained capex, debt paydown, or shareholder returns. Volatility suggests timing of working capital and reinvestment needs can materially alter available cash and funding plans over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized ADC CDMO franchise
A focused ADC CDMO model creates durable competitive advantages: technical know-how across ADC discovery, analytical, and GMP manufacturing raises switching costs, fosters long-term partnerships, and aligns with structural outsourcing by biopharma for complex modalities.
Read all positive factors
WuXi XDC Cayman, Inc. (2268) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$58.87B
Dividend YieldN/A
Average Volume (3M)6.66M
Price to Earnings (P/E)36.4
Beta (1Y)1.16
Revenue Growth46.83%
EPS Growth36.46%
CountryHK
Employees2,041
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)1.20
Shares Outstanding1,260,609,400
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)6.72
Price to Sales (P/S)12.13
P/FCF Ratio113.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$81.58Price Target Upside48.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.62
Revenue Forecast (FY)HK$8.14B
WuXi XDC Cayman, Inc. Business Overview & Revenue Model
Company Description
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company...
How the Company Makes Money
The company primarily makes money by charging pharmaceutical and biotechnology customers service fees under contract development and manufacturing arrangements for ADC programs. Key revenue streams generally include: (1) development services—fees ...
WuXi XDC Cayman, Inc. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.94B | 4.05B | 2.12B | 990.42M | 311.13M |
| Gross Profit | 2.14B | 1.24B | 559.56M | 261.08M | 113.49M |
| EBITDA | 1.77B | 1.33B | 420.28M | 151.75M | 77.37M |
| Net Income | 1.48B | 1.07B | 283.54M | 155.73M | 54.93M |
Balance Sheet | |||||
| Total Assets | 14.44B | 9.12B | 6.74B | 2.50B | 879.75M |
| Cash, Cash Equivalents and Short-Term Investments | 7.47B | 3.97B | 4.05B | 734.97M | 26.32M |
| Total Debt | 879.52M | 496.43M | 2.84M | 77.18M | 24.59M |
| Total Liabilities | 3.71B | 2.48B | 1.28B | 1.02B | 858.87M |
| Stockholders Equity | 10.73B | 6.64B | 5.45B | 1.48B | 20.88M |
Cash Flow | |||||
| Free Cash Flow | 634.64M | -787.95M | -206.51M | 50.43M | 7.23M |
| Operating Cash Flow | 1.85B | 717.22M | 332.85M | 251.82M | 59.14M |
| Investing Cash Flow | -1.43B | -3.33B | -91.23M | -1.28B | -51.59M |
| Financing Cash Flow | 2.80B | 475.36M | 3.52B | 1.33B | 22.34M |
WuXi XDC Cayman, Inc. Technical Analysis
Negative
54.80
Price Trends
55.51
Negative
58.17
Negative
63.48
Negative
Market Momentum
-2.73
Positive
36.81
Neutral
37.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2268, the sentiment is Negative. The current price of 54.8 is above the 20-day moving average (MA) of 50.79, below the 50-day MA of 55.51, and below the 200-day MA of 63.48, indicating a bearish trend. The MACD of -2.73 indicates Positive momentum. The RSI at 36.81 is Neutral, neither overbought nor oversold. The STOCH value of 37.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2268.
WuXi XDC Cayman, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$352.13B | 14.93 | 27.31% | 1.84% | 19.90% | 86.59% | |
70 Outperform | HK$50.24B | 40.40 | 6.34% | 1.57% | 18.78% | 12.65% | |
68 Neutral | HK$43.59B | 24.18 | 11.22% | 1.04% | 16.83% | -8.65% | |
64 Neutral | HK$127.68B | 22.86 | 10.64% | ― | 16.79% | 47.14% | |
63 Neutral | HK$58.87B | 36.35 | 16.29% | ― | 46.83% | 36.46% | |
62 Neutral | HK$35.30B | 42.51 | 3.69% | 0.80% | 10.65% | 134.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2268
WuXi XDC Cayman, Inc.
48.16
7.31
17.89%
HK:2269
Wuxi Biologics (Cayman)
30.74
6.24
25.47%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
31.66
-5.27
-14.26%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
15.25
-0.19
-1.20%
HK:2359
WuXi AppTec Co., Ltd. Class H
132.80
59.67
81.58%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
97.30
26.02
36.50%
WuXi XDC Cayman, Inc. Corporate Events
WuXi XDC Unit BioDlink Signs RMB19 Million Monoclonal Antibody Manufacturing Deal With WuXi Biologics
Jun 16, 2026
WuXi XDC’s subsidiary BioDlink International has signed a process development and manufacturing services agreement with WuXi Biologics, under which BioDlink will produce ten batches of monoclonal antibody intermediates for pilot production b...
WuXi XDC Sets 2026 AGM to Renew Capital-Issuance Mandate
Jun 1, 2026
WuXi XDC Cayman Inc., a Hong Kong–listed biotech services provider incorporated in the Cayman Islands, operates in the biopharmaceutical and biotechnology services industry, supporting global pharma and biotech companies with development and...
WuXi XDC Buys HK$326.5 Million in Shares for Incentive Schemes
May 28, 2026
WuXi XDC Cayman Inc. has completed an on-market purchase of 5,702,000 shares, equivalent to about 0.45% of its issued share capital, through a professional trustee to support its share schemes. The transaction, conducted between May 19 and May 29 ...
WuXi XDC allocates up to US$100 million for on‑market share purchases
May 18, 2026
WuXi XDC Cayman Inc. has authorised the use of up to US$100 million of internal funds for a professional trustee to purchase its shares on the open market to support the company’s share schemes. The board argues that the current share price ...
WuXi XDC Grants 4.85 Million Restricted Shares Under 2024 Incentive Scheme
Apr 8, 2026
WuXi XDC Cayman Inc. has approved the grant of 4,854,500 restricted shares at no purchase price to 425 grantees, including three directors and 422 employees, under its 2024 Share Scheme, with the shares to vest in four equal annual installments st...
WuXi XDC Cash Offers Close With Offeror Gaining Majority Control
Mar 31, 2026
WuXi XDC Cayman Inc. and BioDlink International Company Limited announced the close of voluntary conditional cash offers for WuXi XDC shares and share options, which were made on behalf of the offeror by Citigroup Global Markets Asia. The offeror ...
WuXi XDC Posts Strong 2025 Profit Growth but Withholds Final Dividend
Mar 23, 2026
WuXi XDC Cayman Inc., a Hong Kong-listed biopharmaceutical services provider incorporated in the Cayman Islands, specializes in contract development and manufacturing for innovative therapeutics, serving global pharma and biotech customers. Its bu...
WuXi XDC to Present 2025 Results in Dual Conference Calls on March 24, 2026
Mar 23, 2026
WuXi XDC Cayman Inc. has announced that it will hold two conference calls on March 24, 2026, to present its 2025 annual results and discuss business operations with shareholders and potential investors. The company has also released the full prese...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.